A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Year: 2020
Type: article
Study design: Clinical Trial
Abstract: AZD6244 is a MEK1/2 inhibitor with significant preclinical activity in multiple myeloma (MM) cells. This phase 2 study used a two-stage Simon design to determine the AZD6244 response rate in patients with relapsed or refractory MM.
DOI: 10.17615/jba5-v347
Authors: Roberts, John D., Zingone, Adriana, Voorhees, Peter M., Grant, Steven, Hogan, Kevin T., Doyle, Austin, Sankala, Heidi, Raffeld, Mark, Sullivan, Daniel, Xi, Liqiang, Wan, Wen, Lin, Hui-Yi, Zhao, Xiuhua, Landgren, Ola, Wellons, Martha, Baz, Rachid, Bose, Prithviraj, Badros, Ashraf Z., Weir-Wiggins, Caryn, Herrmann, Michelle, Annunziata, Christina M., Shrader, Ellen, Holkova, Beata, Tombes, Mary Beth, Chen, Jin-Qiu, Kmieciak, Maciej, Korde, Neha
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4300664365